logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Reports New Data From 2 Pivotal Phase III Efficacy Trials For Suvorexant

Merck (MRK: Quote) announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine company is developing for the treatment of insomnia.

In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. Merck noted that the investigational medicine met statistical significance for all primary endpoints except for one measurement at month 3 in one of the trials. These late-breaking data were presented today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

Darryle Schoepp, senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories, stated, "Suvorexant approaches insomnia differently than other medicines because it helps patients to sleep by targeting and blocking orexins, which play a role in keeping people awake. We're excited about the Phase III results and the potential of suvorexant to become the first in a new class of medicines to help patients with insomnia."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Gas explosion in Fresno in California injured 11 people on Friday afternoon. Pacific Gas and Electric Co. (PG&E) said workers who are not affiliated with the company have struck a 12-inch natural gas transmission pipeline and the gas leaked was ignited due to the dig-in. Verizon Communications' FiOS TV service has modified its programming bundles and will now offer new packages so that users can subscribe only for channels they prefer to watch. Instagram, the photo sharing app owned by Facebook, has updated its community guidelines to disallow nudity and harassment in uploaded photos and pictures, as well as cyber bullying.
comments powered by Disqus
Follow RTT